Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Esperion Therapeutics, Inc. (ESPR) had Revenue of $403.13M for the most recently reported fiscal year, ending 2025-12-31.

Quarterly Annual

Figures for fiscal year ending 2025-12-31

Income Statement Financials
Revenue	$403.13M
Net Income	$-22.68M
Cost of Goods Sold	$129.22M
Gross Profit	$273.91M
Operating Expenses	$342.86M
Operating Income	$60.27M
Non-Operating Income/Expense	$-81.11M
Pre-Tax Income	$-20.84M
Normalized Pre-Tax Income	$-20.84M
Income after Taxes	$-22.68M
Income from Continuous Operations	$-22.68M
Consolidated Net Income/Loss	$-22.68M
Normalized Income after Taxes	$-22.68M
EBIT	$60.27M
EBITDA	$63.38M
Weighted-Average Shares Outstanding (Basic)	207.87M
Weighted-Average Shares Outstanding (Diluted)	207.87M
Earnings per Share (EPS) (Basic)	$-0.11
Earnings per Share (EPS) (Diluted)	$-0.11
Balance Sheet Financials
Current Assets	$462.57M
Property, Plant, and Equipment	$0.34M
Long-Term Assets	$3.32M
Total Assets	$465.89M
Current Liabilities	$300.81M
Long-Term Debt	$249.48M
Long-Term Liabilities	$467.04M
Total Liabilities	$767.85M
Common Equity	$-301.96M
Tangible Shareholders Equity	$-302.02M
Shareholders Equity	$-301.96M
Common Shares Outstanding	245.22M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-13.09M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$36.18M
Beginning Cash	$144.76M
End Cash	$167.85M
Increase/Decrease in Cash	$23.09M
Stock-Based Compensation	$9.87M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.54
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-4.75
Debt to Equity Ratio	-0.83
Gross Margin	67.95%
Operating Margin	14.95%
EBIT Margin	14.95%
EBITDA Margin	15.72%
Pre-Tax Profit Margin	-5.17%
Profit Margin	-5.63%
Free Cash Flow	$-13.09M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.87
Inventory Turnover	1.23
Receiveable Turnover	2.88
Days Sales in Receivables	126.93
Return on Equity	7.51%
Return on Tangible Equity	7.51%
Return on Assets	-4.87%
Return on Investments	43.22%
Book Value Per Share	$-1.23
Free Cash Flow per Share	$-0.06
Operating Cash Flow per Share	$-0.06

Data from Zacks Investment Research, Inc.